Novavax Global Commercial Operations and COVID-19 Vaccine Update

Study 311 design: Boost with prototype vs. BA.1 vs. Bivalent • Subjects 18-64 years of age, N=955 • • . • 2 or 3 doses of mRNA COVID vaccine with last dose >90 days prior to enrollment (median = 180 days) Priming series: • 2 doses of mRNA vaccine N=123* 3 doses of mRNA vaccine N = 832 Boost Novavax x1 dose • - Prototype OR Omicron BA.1 OR bivalent ( Prototype + Omicron BA.1) Primary endpoint in individuals with 3 priming doses and baseline anti-N seronegative Open Label ≥ 3 months Prototype Immunology Omicron BA.1 Prior mRNA COVID-19 +/- boost with MRNA COVID vaccines vaccine Bivalent (Prototype + BA.1) Day 0 Day 14 Day 28 novavax * 2 dose group: Last dose at least 180 days prior to boost © 2023 NOVAVAX. All rights reserved. 52

View entire presentation